Bio-Rad Laboratories, Inc. – Consensus ‘Buy’ rating and 34.5% Upside Potential

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

Bio-Rad Laboratories, Inc. which can be found using ticker (BIO) have now 5 market analysts covering the stock. The analyst consensus now points to a rating of ‘Buy’. The target price High/Low ranges between 680 and 550 calculating the mean target price we have $617.40. Now with the previous closing price of $459.07 and the analysts are correct then we can expect a percentage increase in value of 34.5%. Also worth taking note is the 50 day moving average now sits at $475.64 and the 200 day moving average is $457.28. The company has a market cap of $13,813m. You can visit the company’s website by visiting: https://www.bio-rad.com

The potential market cap would be $18,576m based on the market consensus.

Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians’ office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

The company is not paying dividends at this time.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:

      Search

      Search